| Drug Record |
| Accession Number |
| 2004063203. |
| Authors |
| Scharenberg T. | Title |
| Eptifibatide (INTEGRILIN). |
| Source |
| Cinahl Information Systems (Glendale, CA) ** 2004 (11 p) (8 ref) |
| CINAHL Subject Headings |
| *Angina, Unstable/Drug Therapy Drug Administration/Nursing Drug Interactions Education, Continuing (Credit) Hemorrhage/Chemically Induced *Myocardial Infarction/Drug Therapy Myocardial Revascularization Patient Education Platelet Aggregation Inhibitors/Administration and Dosage Platelet Aggregation Inhibitors/Adverse Effects Platelet Aggregation Inhibitors/Contraindications Platelet Aggregation Inhibitors/Pharmacodynamics Platelet Aggregation Inhibitors/Pharmacokinetics *Platelet Aggregation Inhibitors/Therapeutic Use |
| Abstract |
| Aggregation of platelets is the pathophysiologic basis of acute coronary syndromes. Eptifibatide binds to and inhibits the platelet glycoprotein IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation.1 Eptifibatide is used as an adjunct to standard therapies for managing unstable angina or non-Q-wave myocardial infarction, which include aspirin, nitroglycerin, IV heparin, and ss-blockers. Some patients may require more aggressive management with angiographic evaluation and revascularization procedures (e.g., PCI, coronary artery bypass grafting, coronary artery stent implantation).3 In clinical trials, eptifibatide reduced the incidence of the composite endpoint of death or nonfatal myocardial infarction (MI) in patients with acute coronary syndromes who did not have persistent ST-segment elevation. In patients undergoing PCI, eptifibatide has been shown to decrease the rate of the combined endpoint of death, new MI, or need for urgent intervention. Eptifibatide is administered as an intravenous bolus followed by a continuous infusion. Common adverse events from therapy with eptifibatide include bleeding and hypotension.1 |
| [The information in these drug records is as accurate and up to date as possible. However, dosages should always be checked with relevant information sheets. Information can become out of date at any time and up to date information should always be sought. Cinahl Information Systems, its affiliates, employees and contractors cannot be held responsible for any inaccuracies that may occur, or the adverse effects of any particular drug. Decisions regarding drug administration must be made according to the independent judgment of the treating physician in each particular case.] |
| Cited References |
| INTEGRILIN (eptifibatide) prescribing information. 2001. http://www.milennium.com/images/INTEGRILIN (r) insert.Pdf. |
| Drug Facts and Comparisons. St. Louis: Facts and Comparisons; 2002 |
| American Society of Hospital Pharmacists. AHFS drug information. Bethesda, MD: Authority of the Board of Directors of the American Society of Hospital Pharmacists; 2002 |
| The PURSUIT Trial Investigators: Harrington RA, et al. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339(7): 436-443 |
| The IMPACT II Investigators: Tcheng JE, et al. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997; 349(9063): 1422-28 |
| Mahaffey KW, et al. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT) trial. Circulation 1999; 99(18): 2371-2377 |
| The ESPRIT investigators: Tcheng JE, et al. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial. Lancet 2000; 356(9247): 2037-2044 |
| Micromedex.. http://www.micromedex.com. |
| Document Type |
| Drugs. CEU. Consumer/Patient Teaching Materials. Exam Questions. |
| Tables/Charts. |
| Language |
| English |
| Images |
| 2004063203a.pdf; 2004063203b.pdf; 2004063203c.pdf |
| Entry Month |
| 20040514 |